Novo Nordisk (NVO) Partners With Indian Health-Tech Startup

Group 1 - Novo Nordisk A/S has partnered with Indian health-tech startup Healthify to provide nutrition, health, and lifestyle coaching, marking Healthify's first collaboration with a pharmaceutical company [1] - The partnership includes a new patient support program offering coaching services to users prescribed Novo's weight-loss therapies [1] - Despite the partnership, Wall Street has mixed opinions on Novo Nordisk's stock, with a year-to-date share price decrease of 47.86% [1] Group 2 - Morgan Stanley's Thibault Boutherin has lowered the price target for Novo Nordisk from $43 to $42 while maintaining a Sell rating [1] - Berenberg Bank's Kerry Holford reiterated a Buy rating with a price target of $62 [1] - The European Union pharmaceutical sector is expected to remain neutral in 2026, with fundamentals intact but offset by better EPS growth in other sectors [2]